{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:32Z","timestamp":1793664812433,"version":"4.5.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory idiopathic nephrotic syndrome (INS), in native kidneys or post-transplant, represents a major therapeutic challenge due to its high risk of progressing to end-stage renal disease. Patients often resist anti-CD20 therapy and require prolonged apheresis. Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has demonstrated promising efficacy in case reports when combined with anti-CD20, but evidence remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study including four patients (two pediatric, two adult, including one renal transplant) with INS refractory to conventional therapies (corticosteroids, calcineurin inhibitors, mycophenolate mofetil, anti-CD20 antibodies, and\/or apheresis). All Patients received daratumumab combined with anti-CD20 therapy at University Hospital of La R\u00e9union between 2022 and 2025. Clinical and laboratory data were extracted from medical records. Renal response was defined as complete remission (CR) or partial remission (PR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean patient age was 20 \u00b1 13 years (range: 8\u201340), with a male-to-female ratio of 3:1. Median follow-up after daratumumab administration was 5 months (range: 2\u201312). All patients achieved CR with a median time to response of 25 days (range: 14\u201330). Previously apheresis-dependent patients were able to discontinue sessions. Two patients developed infections (herpetic and SARS-CoV-2 pneumonia complicated by pneumococcal bacteremia), all resolving favorably. Renal function remained stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combined daratumumab and anti-CD20 therapy appears to be an effective rescue strategy for refractory INS, in native kidneys and post-transplant. It induces rapid and sustained remission, enabling discontinuation of apheresis. Prospective studies are warranted to optimize treatment regimens and identify predictive biomarkers of response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1722023","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:10Z","timestamp":1764652450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Hamza","family":"Naciri Bennani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sandaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Charroyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Etangsale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Vacher Coponat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dunand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Di Ascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312232","article-title":"Biomarkers to predict or measure steroid resistance in idiopathic nephrotic syndrome: A systematic review","volume":"20","author":"May","year":"2025","journal-title":"PLoS One"},{"key":"B2","article-title":"Diagnosis and management of nephrotic syndrome in adults","volume":"93","author":"Kodner","year":"2016","journal-title":"Am Fam Physician"},{"key":"B3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90437-9","article-title":"Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: A 20-year renal biopsy study","volume":"26","author":"Haas","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04121206","article-title":"A proposed taxonomy for the podocytopathies: A reassessment of the primary nephrotic diseases","volume":"2","author":"Barisoni","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000610","article-title":"Long-term outcomes in nephrotic syndrome by kidney biopsy diagnosis and proteinuria","volume":"36","author":"Pitcher","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.10.021","article-title":"End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population","volume":"93","author":"Sim","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf045","article-title":"Personalized disease recurrence modeling using iPSC-derived podocytes in patients with idiopathic nephrotic syndrome","volume":"40","author":"van den Berge","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3765608","DOI":"10.1155\/2016\/3765608","article-title":"Circulating permeability factors in primary focal segmental glomerulosclerosis: A review of proposed candidates","volume":"2016","author":"K\u00f6nigshausen","year":"2016","journal-title":"BioMed Res Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03800609","article-title":"Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis","volume":"5","author":"McCarthy","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2411","article-title":"Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis","volume":"17","author":"Wei","year":"2011","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07680712","article-title":"Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: A single-center report","volume":"8","author":"Bock","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188045","article-title":"Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS","volume":"12","author":"Doublier","year":"2017","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314471","article-title":"Autoantibodies targeting nephrin in podocytopathies","volume":"391","author":"Hengel","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/nep.14249","article-title":"A pilot study of anti-nephrin antibodies in podocytopaties among adults","volume":"29","author":"Chebotareva","year":"2024","journal-title":"Nephrol (Carlton)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.02.028","article-title":"Anti-nephrin antibodies in adult Chinese patients with minimal change disease and primary focal segmental glomerulosclerosis","volume":"108","author":"Shu","year":"2025","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12882-025-04035-0","article-title":"Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome","volume":"26","author":"Feder","year":"2025","journal-title":"BMC Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu209","article-title":"Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance","volume":"29","author":"Guitard","year":"2014","journal-title":"Nephrol Dial Transpl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.280","article-title":"The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient","volume":"82","author":"Radhakrishnan","year":"2012","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016101121","article-title":"Long-term outcome of steroid-resistant nephrotic syndrome in children","volume":"28","author":"Trautmann","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102671","article-title":"Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown","volume":"19","author":"Gauckler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl805","article-title":"Efficacy and safety of \u2018rescue therapy\u2019 with mycophenolate mofetil in resistant primary glomerulonephritis\u2013a multicenter study","volume":"22","author":"Segarra","year":"2007","journal-title":"Nephrol Dial Transpl"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12882-016-0322-7","article-title":"The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series","volume":"17","author":"Kashgary","year":"2016","journal-title":"BMC Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010093","article-title":"Kidney transplantation for focal segmental glomerulosclerosis: can we prevent its recurrence? Personal experience and literature review","volume":"11","author":"Naciri Bennani","year":"2021","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06720810","article-title":"Posttransplant recurrence of primary glomerulonephritis","volume":"5","author":"Ponticelli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.21311","article-title":"Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States","volume":"37","author":"Abbott","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.03.015","article-title":"Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes","volume":"92","author":"Allen","year":"2017","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and daratumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am J Transpl"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2024.06.010","article-title":"Rescue with obinutuzumab and daratumumab as combined B cell\/plasma cell targeting approach in severe posttransplant focal segmental glomerulosclerosis recurrence","volume":"24","author":"Randone","year":"2024","journal-title":"Am J Transpl"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04519-1","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome","volume":"35","author":"Trautmann","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14544","article-title":"Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab","volume":"27","author":"Delbet","year":"2023","journal-title":"Pediatr Transpl"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04811-0","article-title":"A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome","volume":"36","author":"Dossier","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.015","article-title":"Anti-nephrin antibodies guide living donor kidney transplantation in a pediatric patient with primary focal segmental glomerular sclerosis","volume":"108","author":"Habbig","year":"2025","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.11.022","article-title":"A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence","volume":"105","author":"Shirai","year":"2024","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213203","article-title":"Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment","volume":"14","author":"Angeletti","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.07.038","article-title":"Daratumumab efficacy in steroid-resistant nephrotic syndrome correlates with CD38+ B-cell depletion","volume":"10","author":"Bigatti","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.726428","article-title":"CyTOF-enabled analysis identifies class-switched B cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome","volume":"12","author":"Fribourg","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.06.013","article-title":"Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing\/steroid-dependent nephrotic syndrome","volume":"104","author":"Colucci","year":"2023","journal-title":"Kidney Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.06.019","article-title":"Obinutuzumab in rituximab-resistant podocytopathies: A single-center experience","volume":"10","author":"Angeletti","year":"2025","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:11Z","timestamp":1764652451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2025.1722023"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722023","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1722023"}}